[1]
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 189-202.
[2]
Collaborators GBDD. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 88-106.
[3]
Doody RS, Raman R, Farlow M, et al. Alzheimer’s disease Cooperative Study Steering C, Siemers E, Sethuraman G, Mohs R, Semagacestat Study G. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013; 369: 341-50.
[4]
Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018; 378: 321-30.
[5]
Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med 2019; 380: 1408-20.
[6]
Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016; 388: 2873-84.
[7]
Guzman-Martinez L, Calfio C, Farias GA, Vilches C, Prieto R, Maccioni RB. New frontiers in the prevention, diagnosis, and treatment of Alzheimer’s disease. J Alzheimers Dis 2021.
[8]
Jefferson AL, Hohman TJ, Liu D, et al. Adverse vascular risk is related to cognitive decline in older adults. J Alzheimers Dis 2015; 44: 1361-73.
[9]
Tu L, Lv X, Yuan C, et al. Trajectories of cognitive function and their determinants in older people: 12 years of follow-up in the Chinese Longitudinal Healthy Longevity Survey. Int Psychogeriatr 2020; 32: 765-75.
[10]
Malden DE, Mangoni AA, Woodman RJ, et al. Circulating asymmetric dimethylarginine and cognitive decline: A 4-year follow-up study of the 1936 Aberdeen Birth Cohort. Int J Geriatr Psychiatry 2020.
[11]
McEvoy M, Schofield P, Smith W, et al. Memory impairment is associated with serum methylarginines in older adults. Curr Alzheimer Res 2014; 11: 97-106.
[12]
Rochoy M, Rivas V, Chazard E, et al. Factors associated with Alzheimer’s disease: An overview of reviews. J Prev Alzheimers Dis 2019; 6: 121-34.
[13]
Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail 2018; 6: 179-86.
[14]
Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: A network meta-analysis. Circ Heart Fail 2017; 10.
[15]
Wang K, Hu J, Luo T, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: A systematic review and meta-analysis. Kidney Blood Press Res 2018; 43: 768-79.
[16]
Oscanoa TJ, Amado J, Vidal X, Romero-Ortuno R. Angiotensin-receptor blockers and the risk of Alzheimer’s Disease: A meta-analysis. Curr Clin Pharmacol2021 in press
[17]
Yasar S, Xia J, Yao W, et al. Ginkgo Evaluation of Memory Study I. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study. Neurology 2013; 81: 896-903.
[18]
Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer’s disease: Risk factors and potentially protective measures. J Biomed Sci 2019; 26: 33.
[19]
den Brok M, van Dalen JW, Abdulrahman H, et al. Antihypertensive medication classes and the risk of dementia: A systematic review and network meta-analysis. J Am Med Dir Assoc 2021.
[20]
Peters R, Yasar S, Anderson CS, et al. Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. Neurology 2020; 94: e267-81.
[21]
Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: A meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol 2020; 19: 61-70.
